MedTrace Logo

Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage

NCT03741530 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2022-04-08

No results posted yet for this study

Summary

The purpose of the present study is to explore the efficacy of small doses of oral glibenclamide on brain edema after acute primary intracerebral hemorrhage (ICH), and improving the prognosis of patients.

Conditions

  • Intracerebral Hemorrhage

Interventions

DRUG

Glibenclamide Tablets

Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.

OTHER

Standard management for ICH

Usual care and drug in hospital

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Wen Jiang, PhD · Department of Neurology, Xijing Hospital, Fourth Military Medical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-15
Primary Completion
2020-09-23
Completion
2020-09-23

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03741530 on ClinicalTrials.gov